|Chairman of the Board
Representative Executive Officer, Executive Chairman
|Shinichi founded Sosei in June 1990 as a technology transfer company, having built up a wealth of experience during his years in the industry. He graduated from Tokyo University with an M.S. in Biochemistry and a major in Cultural Anthropology, going on to work in various positions in Planning and Development at Fujisawa Pharmaceutical Co. Ltd.
Shinichi was later appointed Representative Director (CEO) of Genentech Limited (Genentech Inc's Japan subsidiary). He has advised various companies including Genentech, GenPharm, Geron, IDEC, Pharmacyclics, and Vernalis, and played an important role in completing several significant deals.
Representative Executive Officer, CEO
|Peter has more than two decades of experience in the pharmaceutical industry encompassing strategic and operational leadership expertise across global geographies, functions and business segments. He had a 23-year career at GlaxoSmithKline, where he held multiple senior roles including General Manager of China, Head of Global Marketing and Senior VP of International Commercial Operations. From 2009, he has been a consultant specialising in supporting strategic growth opportunities in small- and medium-sized innovation-based life science companies; Syngene, a subsidiary of Biocon, Asia's largest biotechnology company; and Kromek Ltd, an AIM-listed company. He is also Non-executive Chairman of Fermenta Biotech Ltd, a subsidiary of DIL, a Mumbai-listed company. Peter completed his B.Sc Combined Honours in Physiology/ Zoology from Sheffield University.|
|Declan received his Medical degree from Glasgow University in 1975 and joined Pfizer in 1982, where he was in charge of the sertraline® (Zoloft) clinical development programme. He has held a number of senior positions in research and development in Pfizer in the United States, United Kingdom, and Japan. He retired from Pfizer in 2007 as the Head of Worldwide Development. Declan has since held the positions of Interim CEO and Chief Medical Officer of Amarin Corporation. He is Executive Chairman of Biohaven Pharmaceuticals, CEO of Portage Biotech and co-founder and managing partner of Topix.
Declan is on the Board of the not-for-profit Pulmonary Vascular Research Institute. He has held Visiting Professorships at Harvard School of Public Health, Glasgow University Medical School, and Kitasato University (Tokyo) and is Adjunct Professor of Psychiatry at the University of Cork. He is a Fellow of the Royal College of Physicians and the Faculty of Pharmaceutical Medicine in the United Kingdom and received a Doctorate of Science from the University of Kent, UK.
|Tomohiro is a partner at TMI Associates, which he co-founded in October 1990.
Tomohiro entered the Legal Training and Research Institute, Supreme Court of Japan in April 1978 and registered with Dai-ichi Tokyo Bar Association in April 1980. He joined Nishimura and Sanada Law Office in April 1980, becoming a partner in August 1985. He has also held positions at law firms Mason & Sloane, LLP. USA., Pollock, Bloom & Dekom, USA, and Pryor, Cashman, Sherman & Flynn, USA.
Tomohiro has been Outside Director of Nippon Shikizai, Inc. since November 1999, Outside Statutory Auditor of WOWOW INC. since June 2016, and Outside Director of Trust Capital Co., Ltd. since May 2016. He joined the External Board of Sosei Group Corporation in 2010.
|Julia P. Gregory received her M.B.A. from The Wharton School of The University of Pennsylvania and her B.A. in International Affairs with a minor in International Economics from George Washington University's Elliott School of International Affairs where she was elected to Phi Beta Kappa. She is currently Chairman and CEO of Isometry Advisors, Inc., a biotechnology financial and management advisory firm, has 16 years of biotechnology executive management experience and 20 years of investment banking experience. As an executive, she successfully raised more than $1.5 billion for her companies through initial public offerings, public and private offerings and creative strategic alliances with GlaxoSmithKline, BristolMyers Squibb, Takeda Pharmaceuticals, Genentech, (Roche) and Human Genome Sciences (GSK), among others. Recently, she was CEO of ContraFect Corporation, which focused on new biologics as an alternative to antibiotics. Prior to ContraFect, she was CEO of FivePrime Therapeutics, where she led a clinical-stage, biotechnology company discovering and developing innovative protein and antibody therapeutics in oncology and immunology; and was EVP, Head of Corporate Development and CFO of Lexicon Pharmaceuticals which identified the function of 5,000 genes, resulting in more than 100 protein targets with therapeutic potential in a range of diseases and a recently commercialized drug for carcinoid syndrome diarrhea. She is currently on the board of directors of Iconic Therapeutics and is an Advisor Partner to the Morgan Stanley Expansion Capital Fund.|
|Chairman of the Board
Representative Executive Officer, Chief Executive Chairman
Representative Executive Officer, CEO
|Executive Vice President, CFO|
|Andrew’s diverse experience in holding CFO positions over the past 14 years brings to the firm expertise and leadership with a particularly strong focus in the biotechnology sector. He holds a Bachelor of Economics Degree from Macquarie University and an MBA from London Business School and has been a Member of the Australian Institute of Chartered Accountants since 1987. In his last position before joining Sosei, he was the Chief Financial Officer, Company Secretary and Executive Board Member of British-based bio-pharmaceutical company Vectura PLC. Prior to joining Vectura, he was the Chief Financial Officer at the Swiss bio-pharmaceutical company Actelion Ltd, where he led the finance function for over a decade. He also previously served in a senior finance capacity for the global holding companies of Accenture, having previously held executive positions in major multinational building material companies, and has also spent several years as an equity analyst with banks in Australia, the UK and the US.|
|Executive Vice President, Chief R&D Officer|
|Former Visiting Professor of Biochemistry at Imperial College, London
Former Head of the Molecular Sciences Division of Glaxo Wellcome Inc. (present Glaxo Smithkline plc.)
Former CEO of Inpharmatica Ltd.（present Galapagos NV)
Founder and CEO of Heptares Therapeutics Ltd.
|Chief Medical Officer and VP of Development|
|Tim is a physician and clinical pharmacologist with more than 30 years of industry experience from both large pharmaceutical and small biotechnology companies. He spent over 20 years at GlaxoSmithKline and led all of its Phase 1 Clinical Research Units (in the US, UK, Europe and Australia), which supported the Centres of Excellence in Drug Discovery across all therapeutic areas. After GSK, he joined Evotec as Executive VP of Clinical Development, at which he was instrumental in advancing novel compounds to Phase 2 proof of concept studies. Dr Tasker then set up his own consulting firm providing high-level, early drug development expertise to companies in Europe, Australia and Japan. Dr Tasker is a Fellow of the UK Royal College of Physicians and of the UK Faculty of Pharmaceutical Medicine.
Tim is is Executive VP and Chief Medical Officer of Sosei Group Corporation.